Please assess the completion status of the following clinical trial:

Trial Title: Miglustat / OGT 918 in the Treatment of Cystic Fibrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 12 years and older~* Male or female~* Non-pregnant women who are to remain non-pregnant for 3 months after the end of the study: only women who are surgically sterile, who are in the menopause (no menstruation for at least one year) or those of childbearing potential who are using a reliable method of contraception. Reliable methods of contraception for female patients include the following:~  * Barrier type devices (e.g., female condom, diaphragm and contraceptive sponge) used ONLY in combination with a spermicide~ * Intrauterine devices~ * Oral contraceptive agent~ * Depo-Provera™ (medroxyprogesterone acetate)~ * Levonorgestrel implants Abstention, the rhythm method or contraception by the partner alone are NOT reliable methods of contraception.~For children, a reliable method of contraception must be considered, if appropriate.~* Accepting for the duration of the study and for 3 months thereafter to use a condom and not to procreate a child (males only)~* Cystic fibrosis patients homozygous for the ΔF508 mutation as confirmed by genetic test~* Signed informed consent prior to any study-mandated procedure~Exclusion Criteria:~* Any condition prohibiting the correct measurement of the NPD such as upper respiratory tract infection~* Acute upper respiratory tract or pulmonary exacerbation requiring antibiotic intervention within 2 weeks of screening~* Severe renal impairment (creatinine clearance \< 30 ml/min as per Cockroft and Gault)~* Female patients who will not undergo a pregnancy test prior to enrollment in the study~* History of significant lactose intolerance~* History of neuropathy~* History of cataracts or known increased risk of cataract formation~* Presence of clinically significant diarrhea (\>3 liquid stolls per days for \>7 days) without definable cause within 1 month prior to screening~* Any known factor of disease that might interfere with treatment compliance, study conduct or interruption of the results such as drug or alcohol dependence or psychiatric disease~* FEVI \<25% of predicted normal~* Oxygen saturation at rest \<88%~* Active or passive smoking as measured using the Smokelyzer®~* Hypersensitivity to miglustat or any excipients~* Planned treatment or treatment with another investigational drug or therapy (e.g., gene therapy) within 1 month prior to randomization

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Oral miglustat capsules 200 mg t.i.d. for 1 week and a single 200 mg dose on day 8
- B (Type: PLACEBO_COMPARATOR): Oral placebo capsules matching in appearance miglustat capsules given t.i.d. for 1 week and a single dose on day 8

Based on this trial design, predict the completion outcome and termination type (if applicable).